The role of miRNAs in viral myocarditis, and its possible implication in induction of mRNA-based COVID-19 vaccines-induced myocarditis
-
Published:2022-11-17
Issue:1
Volume:46
Page:
-
ISSN:2522-8307
-
Container-title:Bulletin of the National Research Centre
-
language:en
-
Short-container-title:Bull Natl Res Cent
Author:
AbdelMassih AntoineORCID, Agha Hala, El-Saiedi Sonia, El-Sisi Amal, El Shershaby Meryam, Gaber Hanya, Ismail Habiba-Allah, El-Husseiny Nadine, Amin Abeer Reda, ElBoraie Aly, Ayad Aya, Menshawey Esraa, Sefein Fady, Osman Ibrahim Ihab, Moursi Mai, Hanafy Maram, Abdelaziz Mariam Sherif, Arsanyous Mariem Badr, Khaled-Ibn-El-Walid Mariam, Tawfik Marwa Gamal, Habib Menna, Mansour Mina Ehab, Ashraf Mirette, Khattab Mohamed Ayman, Alshehry Nada, Hafez Nada, ElDeeb Naheel Essam, Ashraf Nirvana, Khalil Noha, AbdElSalam Noheir Ismail, Shebl Noura, Hafez Nouran Gamal Ali, Youssef Nourhan Hatem, Bahnan Odette, Ismail Passant, Kelada Peter, Menshawey Rahma, Saeed Rana, Husseiny Reem Jalal, Yasser Reem, Sharaf Safa, Adel Veronia, Naeem Youstina, Nicola Youstina Nagy Farid, Kamel Aya, Hozaien Rafeef, Fouda Raghda
Abstract
Abstract
Background
Several reports of unheeded complications secondary to the current mass international rollout of SARS-COV-2 vaccines, one of which is myocarditis occurring with the FDA fully approved vaccine, Pfizer, and others.
Main body of the abstract
Certain miRNAs (non-coding RNA sequences) are involved in the pathogenesis in viral myocarditis, and those miRNAs are interestingly upregulated in severe COVID-19. We hypothesize that the use of mRNA-based vaccines may be triggering the release of host miRNAs or that trigger the occurrence of myocarditis. This is based on the finding of altered host miRNA expression promoting virus-induced myocarditis.
Short conclusion
In conclusion, miRNAs are likely implicated in myocarditis associated with mRNA vaccines. Our hypothesis suggests the use of miRNA as a biomarker for the diagnosis of mRNA vaccine-induced myocarditis. Additionally, the interplay between viral miRNA and the host immune system could alter inflammatory profiles, hence suggesting the use of therapeutic inhibition to prevent such complications.
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Aimo A, Cerbai E, Bartolucci G, Adamo L, Barison A, Lo Surdo G, Biagini S, Passino C, Emdin M (2020) Pirfenidone is a cardioprotective drug: mechanisms of action and preclinical evidence. Pharmacol Res 155:104694. https://doi.org/10.1016/j.phrs.2020.104694 2. Bozkurt B, Kamat I, Hotez PJ (2021) Myocarditis with COVID-19 mRNA vaccines. Circulation 144(6):471–484. https://doi.org/10.1161/CIRCULATIONAHA.121.056135 3. Buscaglia LEB, Li Y (2011) Apoptosis and the target genes of microRNA-21. Chin J Cancer 30(6):371–380. https://doi.org/10.5732/cjc.011.10132 4. Calderon-Dominguez M, Trejo-Gutierrez E, González-Rovira A, Beltrán-Camacho L, Rojas-Torres M, Eslava-Alcón S, Sanchez-Morillo D, Calderon-Dominguez J, Martinez-Nicolás MP, Gonzalez-Beitia E, Nieto-Martín MD, Trujillo-Soto T, Rodríguez-Iglesias MA, Moreno JA, Moreno-Luna R, Durán-Ruiz MC (2022) Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients. Mol Ther Nucleic Acids 29:76–87. https://doi.org/10.1016/j.omtn.2022.06.006 5. Chen X, Dong S, Zhang N, Chen L, Li M-G, Yang P-C, Song J (2017) MicroRNA-98 plays a critical role in experimental myocarditis. Int J Cardiol 229:75–81. https://doi.org/10.1016/j.ijcard.2016.11.263
|
|